History: 2010 till nowadays
2010
Bio-Manguinhos signs agreement of inactivated yellow fever vaccine with the Fraunhofer to develop the vaccine from a vegetable platform.
The Institute signs a contract for technology transfer of the rapid test Dual Path Platform (DPP®) to diagnose syphilis. Records for three products are obtained: rotavirus vaccine, confirmatory test for HIV-1/2 and Nucleic Acid kit (NAT) for HIV and HCV (hepatitis C). Concerning the pentavalent vaccine, which protects against diphtheria, tetanus and pertussis (DTP), Haemophilus influenzae b (Hib) and hepatitis B, had their clinical studies completed.
2011
As part of the schedule to celebrate the 35th anniversary of the foundation, Bio-Manguinhos promotes the II International Symposium of immunobiologicals. Renowned experts in biotechnology have gathered to discuss the future of Brazilian and worldwide health in the area of vaccines, biopharmaceuticals, reagents for laboratory diagnosis and regulations. It is signed a contract with the company Sanofi Pasteur, which make it possible for the unit to provide and, subsequently, to produce the inactivated polio vaccine.
In a ceremony with the President Dilma Rousseff and the Minister of Health, Alexandre Padilha, in Rio de Janeiro, it is signed the official term of cession of a plot of 580,000 m2, in Santa Cruz (Rio de Janeiro). On the site, it will be built the new Center for Final Processing (NCPFI) of the unit. While the industrial plant, which will produce immunobiologicals from plant platforms, is under construction, it will be occupied 225,000 m2 in the Industrial Pole of Health, in Eusébio County (Ceará).
Five rapid tests are introduced with the technology Dual Path Platform (DPP®), which assures faster, accurate and safe results: syphilis, canine visceral leishmaniasis, immunoblot HIV-1/2, leptospirosis and screen HIV-1/2. The project “Growing up with Manguinhos”, from the Socioenvironmental Responsibility Commission (add) meet 86 people from neighboring communities, among youngster and their families.
2012
Bio-Manguinhos obtains authorization, by representatives from all units of the Foundation, to create a federal public company.
In his fifth participation in the Rio Quality Award (PQRio), Bio-Manguinhos conquers the silver category, in the evaluation that recognizes public and private organizations in the state that stood out for excellence in the management model.
The Institute provides to the National Immunization Program (NIP) more than 103 million doses of vaccine and exported 10 million to UN agencies.
From the second half of the year, the institute initiates the supply of viral tetravalent vaccine. Combined with the MMR, the new vaccine will immunize against measles, mumps, rubella and varicella (Chickenpox).
It is created the page Bio on Facebook, representing a further means of communication with its various public interest.
The construction of two Bio-Manguinhos new campuses in Santa Cruz (RJ) and Eusébio (CE) began; the executive project of the New Final Processing Center for Immunobiologicals (NCPFI) that will be located in the west zone of the city of Rio de Janeiro. In addition to the environmental impact assessment of the land was completed; the preparation of the construction site began and it was ratified the commitment of the government of Ceará state about the grant of the land for the new Fiocruz campus.
2013
Through technology transfer with the Israeli company Protalix, Bio-Manguinhos will produce the biopharmaceuticals alfataliglicerase, which combat the Gaucher disease. In addition, the Institute has signed 10 intentions of partnership for productive development (PDP), besides the partnership with the Bill and Melinda Gates Foundation, for the first phase of clinical studies aiming at the development of the double viral vaccine (measles and rubella).
It is granted scientific cooperation with the pharmaceutical company Sanofi Pasteur and partnership with Butantan Institute and Funed to develop the heptavalent vaccine (DTP, HIB, Hepatitis B, hepatitis B, polio inactivated).
Is opened in June the Coordinator Center of Clinical Researches Heitor Beltão, in Tijuca, where Bio will conduct their clinical research.
The unit receives the visit of the President of Opas, Carissa Etienne, who came to know the project of NCPFI.
The unit was visited by Carissa Etienne, president of OPAS, who learned about the new CPFI project. Brazil was her first destination after her inauguration on February 1st.
2014
At the new laboratory of dengue fever, it will be analyzed all samples of epidemiologic and clinical studies conducted in Brazil, Mercosur and Asia.
The test for diagnosing DPP® HIV-1/2 was used for serological screening by means of a drop of blood, serum or plasma. From 2014, it was possible to use oral fluid as well.
The Institute has succeeded in obtaining the records of the alfataliglicerase and rapid test DPP® Syphilis DUO.
The kit NAT, which detected HIV (AIDS virus) and HCV (hepatitis C virus), now has a new target, the HBV (hepatitis B virus).
The partnership between Bio-Manguinhos and the Bill and Melinda Gates Foundation for the production of the double viral vaccine (measles and rubella) competed for the Award of Excellence of the vaccine industry, organization Vaccination, in the category of best partnership.
Akira Homma is elected as one of the most influential people in the vaccine industry. The President of the Political and Strategic Council of Bio-Manguinhos (CPE) won the 20th position.
2015
Signing of contract of technology transfer, the biopharmaceutical Beta interferon 1a, indicated for the treatment of multiple sclerosis, with companies Merck and Bionovis.
Start of the clinical study phase I of the double viral vaccine (measles and rubella).
Renewal of the certificate of GMP, by Anvisa, for the lines of vaccines and biopharmaceuticals.
Obtaining of the register of three products: rapid test DPP® HIV/Syphilis, the infliximab and tetraviral vaccine.
Industrial Complex of biotechnology in health (CIBS) in Santa Cruz: beginning of the planting of 30,000 seedlings of native trees of the rain forest to form the green belt around the ground. Preparation for the step of stem cutting and beginning of the 2nd phase of landscaping.
With the expansion of the CPFI, the ability of the formulation of vaccines will grow by 200%. The aseptic simulations are planned to begin in February.
Back to the "History: 1976-1980" page
2001
2004
2005
2006
2008
2009